Page last updated: 2024-09-05

sorafenib and abt 869

sorafenib has been researched along with abt 869 in 12 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(abt 869)
Trials
(abt 869)
Recent Studies (post-2010) (abt 869)
6,5207305,251841559

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)abt 869 (IC50)
Aurora kinase AHomo sapiens (human)0.76
Cyclin-dependent kinase 1Homo sapiens (human)9.8
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.0321
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)1.9
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0492
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0313
Fibroblast growth factor receptor 1Homo sapiens (human)5.479
AromataseHomo sapiens (human)0.0418
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.015
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.0364
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.1309
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.0312
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.0126
Cyclin-dependent kinase 8Homo sapiens (human)2.158
Angiopoietin-1 receptorHomo sapiens (human)0.0601
Cyclin-dependent kinase 19Homo sapiens (human)0.024

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (8.33)29.6817
2010's11 (91.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Russu, WA; Shallal, HM1
Chang, YI; Chao, YS; Chen, CP; Chen, CT; Chen, CW; Cheng, AH; Chou, LH; Hsieh, SY; Hsu, JT; Hsu, T; Huang, YL; Jiaang, WT; Lin, WH; Lu, CT; Tseng, YJ; Yeh, TK; Yen, KR; Yen, SC1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Chang, YI; Chao, YS; Chen, CH; Chen, CT; Chiu, CH; Chou, LH; Hsieh, SY; Hsu, JT; Hsu, T; Jiaang, WT; Lin, WH; Lu, CT; Tseng, YJ; Yeh, TK; Yen, KR; Yen, SC1
Chao, YS; Chen, CH; Chen, CP; Chen, CT; Chiu, CH; Chou, LH; Hsieh, SY; Hsu, JT; Hsu, T; Jiaang, WT; Lin, WH; Lu, CT; Song, JS; Tseng, YJ; Yang, YN; Yeh, CF; Yeh, TK; Yen, KJ; Yen, SC1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Adeniji-Popoola, O; Blagg, J; Blaukat, A; Box, G; Clarke, PA; Court, W; Czodrowski, P; Dale, T; de Haven Brandon, A; Eccles, SA; Esdar, C; Ewan, K; Fraser, E; Gowan, S; Mallinger, A; Musil, D; Ortiz-Ruiz, MJ; Poeschke, O; Raynaud, F; Rohdich, F; Samant, RS; Schiemann, K; Schneider, K; Schneider, R; Schwarz, D; Stubbs, M; TePoele, R; Valenti, M; Waalboer, D; Wienke, D; Workman, P1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Kumarasiri, M; Philip, S; Teo, T; Wang, S; Yu, M1
Cainap, C; Carlson, DM; Chen, PJ; Cheng, Y; Chung, IJ; El-Nowiem, S; Eskens, FA; Gorbunova, V; Huang, WT; Kang, YK; Kudo, M; McKee, MD; Pan, H; Qian, J; Qin, S; Ricker, JL; Toh, HC1

Reviews

1 review(s) available for sorafenib and abt 869

ArticleYear
Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
    Journal of medicinal chemistry, 2018, 06-28, Volume: 61, Issue:12

    Topics: Antineoplastic Agents; Cyclin-Dependent Kinase 8; Cytokines; Humans; Male; Molecular Targeted Therapy; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Transcription Factors; Tumor Escape

2018

Trials

1 trial(s) available for sorafenib and abt 869

ArticleYear
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jan-10, Volume: 33, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Risk Factors; Sorafenib; Treatment Outcome

2015

Other Studies

10 other study(ies) available for sorafenib and abt 869

ArticleYear
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Bioorganic & medicinal chemistry, 2011, Jul-15, Volume: 19, Issue:14

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Mice; Molecular Structure; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Sorafenib; Stereoisomerism; Structure-Activity Relationship; Sulfonamides

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Bioorganic & medicinal chemistry letters, 2012, Jul-15, Volume: 22, Issue:14

    Topics: Amines; Animals; Antineoplastic Agents; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Mice; Molecular Structure; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2012
Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Bioorganic & medicinal chemistry, 2013, Jun-01, Volume: 21, Issue:11

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Mice; Protein Kinase Inhibitors; Sensitivity and Specificity; Structure-Activity Relationship; Urea; Xenograft Model Antitumor Assays

2013
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
    Nature chemical biology, 2015, Volume: 11, Issue:12

    Topics: Cell Line, Tumor; Colonic Neoplasms; Cyclin-Dependent Kinase 8; Cyclin-Dependent Kinases; Humans; Models, Molecular; Molecular Probes; Molecular Structure; Protein Kinase Inhibitors; Pyridines; Spiro Compounds

2015
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017